PATIENTS' INVOLVEMENT IN THE ERNs: the European Patient Advocacy Groups

Patient representatives and organisations are as integral to the strategic and operational outcomes of European Reference Networks in rare diseases (ERN) and play an active role in the networks' decision and opinion-making structures. To achieve this, EURORDIS created the European Patient Advocacy Groups (ePAGs) as forums to optimise the involvement of patient

representatives of the rare disease community in the 24 ERNs.

ePAGs aim to represent the voice of patients within ERNs to ensure that the needs of people living with a rare disease are included Vera Guimaraes in the strategic and operational delivery of **LPCDR** the network. ePAGs create a bridge between Núcleo MCTE the ERN and the patient community, to ultimately ensure that ERN services can answer to the needs and expectations of rare disease patients and therefore improve access to high quality diagnosis, care and treatment. ePAG Patient Advocates have an official permanent mandate to represent ePAG member organisations. They liaise with these organisations to ensure true and equitable representation of the patient voice by participating in the **Board** and sub-clinical committees of their respective ERN. ePAGs deliver these aims through their ePAG Patient Advocates undertaking the following activities inside the ERN:

• engage with the appropriate patient communities for disease specific activities and projects to represent their needs;

• actively participate to the ERN **Governance structures** and to the ERN activities:

 contribute to the development of information for patients and support the network in the **dissemination** of information and communication to the wider patient community:

- participate to the development of a monitoring process of the **outcomes** of the ERN;
- contribute to the development of **research priorities** and ensure they are informed by the needs of patients and families;
- provide advice on **ethical issues** on the application of personal data protection rules compliance of informed consent and handling of complaints.

ERN ReCONNET ePAG

Jürgen Grunert

Alain Cornet

LPCDR

Charissa Frank

Bindweefsel.Be

One of the most relevant added value of the ERN ReCONNET is the involvement of Patients' Representatives within all the activities of the Network.

In fact, an intense collaboration has been established with the ERN ReCONNET European Patient Advocacy Group (ePAGs).

Three ERN ReCONNET ePAGs Representatives are **voting members** of the Steering Committee, and each Representative represents one arm of the Network: Charissa Frank (Hereditary Connective Tissue Diseases), Ilaria Galetti (Rare Connective Tissue

Diseases), Ana Vieira (Complex Connective Tissue Diseases).

In order to provide a structure to the patients' involvement in the ERN ReCONNET, a Patients Working Group has been

created and Jürgen Grunert will act as Senior Coordinator and Ilaria Galetti as Junior

In addition, Patients' Representative Disease Coordinators (one per each disease) collaborate with Healthcare Providers Disease Coordinators and their role is particularly important for the activities related to the specific diseases both at European



Diseases covered by ERN ReCONNET

Idiopathic Inflammatory Myopathies

IqG4-Related Disease

Mixed Connective Tissue Disease

Relapsing Polychondritis

Siögren's Syndrome

Systemic Lupus Erythematosus

Systemic Sclerosis

Undifferentiated Connective Tissue Disease

Clinical Patient Management System

The Clinical Patient Management System (CPMS) allows healthcare providers from all over the EU to organise virtual consultations and share experience together across national borders. This will provide patients with the **best expertise** available on diagnosis and treatments of rCTDs.



Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET)

How to become an ePAG representative

ePAG patient advocates must come from a patient organisation in the EU and must adhere to the EURORDIS Charter of Volunteers. The number of patient advocates per ePAG is determined in collaboration with clinical coordinating teams of ERN applications and according to the scope of the respective ePAG membership. Patient advocates have already been elected to numerous ERNs but additional applications are welcome for all networks. Members and non-members of EURORDIS are encouraged to apply. If you are interested in becoming an ePAG advocate please contact lenja.wiehe@eurordis.org.

How to become an ePAG member organisation

Membership of ePAGs is open to all rare disease patient organisations (EURORDIS members and non-members based in the European Union). To register the interest of your patient organisation in becoming an ePAG member organisation you should fill out a form (available at https://www.eurordis.org/content/epags) indicating which ERN you wish to be affiliated to.

Network Coordinator Prof. Marta Mosca Azienda Ospedaliero Universitaria Pisana Via Roma, 67 - 56126 Pisa (Italy)







Subscribe to the ReCONNET Newsletter on website



Follow us on Twitter @ern_reconnet Subscribe to our YouTube channel



ERN ReCONNET is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission. The content of this publication represents the views of the authors only and it is their sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

ERN ReCONNET

European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases

Patients' Involvement



for rare or low prevalence complex diseases

Network

Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET)

Share. Care. Cure.

More info:

http://reconnet.ern-net.eu



